No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VRNA240816C5000
- 18.12
- 0.000.00%
15min DelayTrading Jul 18 09:42 ET
0.00High0.00Low
0.00Open18.12Pre Close0 Volume2 Open Interest5.00Strike Price0.00Turnover258.09%IV1.58%PremiumAug 16, 2024Expiry Date17.76Intrinsic Value100Multiplier25DDays to Expiry0.36Extrinsic Value100Contract SizeAmericanOptions Type0.9948Delta0.0010Gamma1.28Leverage Ratio-0.0050Theta0.0034Rho1.27Eff Leverage0.0009Vega
Intraday
- 5D
- Daily
News
Verona Pharma Is Maintained at Buy by Canaccord Genuity
Verona Pharma Is Maintained at Buy by Canaccord
Express News | Verona Pharma PLC : Canaccord Genuity Raises Target Price to $37 From $35
Analysts Have Conflicting Sentiments on These Healthcare Companies: Astellas Pharma (OtherALPMF) and Verona Pharma (VRNA)
CCORF Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $37
CCORF analyst Edward Nash maintains $Verona Pharma(VRNA.US)$ with a buy rating, and adjusts the target price from $35 to $37.According to TipRanks data, the analyst has a success rate of 42.4% and a
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday; Set to End Week Down 4%
European equities traded in the US as American depositary receipts were trending modestly lower Friday, declining 0.37% to 1,410.60 on the S&P Europe Select ADR Index.The index is set to end the
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday
European equities traded in the US as American depositary receipts were moving moderately lower late Thursday morning, declining 0.72% to 1,423.26 on the S&P Europe Select ADR Index.From continental
Comments
$Verona Pharma(VRNA.US$ and finally it seems all brakes are loose and it is going to the top!
1
$Verona Pharma(VRNA.US$ Price pressure has begun in pre-market, which looks unreal for a company receicing approval for a novel - and potentially groundbreaking - drug.
Stay calm, dont play in the hands of the shorts. Make sure your stock cannot be borrowed for shorts as well.
Stay calm, dont play in the hands of the shorts. Make sure your stock cannot be borrowed for shorts as well.
4
1
$Verona Pharma(VRNA.US$ shorters will try to push it down. this is a long term hold being a blockbuster drug, with a 2 billion potential further down the road. revenue forecast for this year 40 million. hopefully conference call is giving the price a boost. if a big pharma might do a take over, it goes sky rocketing. whatever it is, don’t sell cheap. Disclaimer: not financial advice.
5
$Verona Pharma(VRNA.US$ Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine) 2 HOURS AGO, 4:57 PM EDT VIA GLOBENEWSWIRE: Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH,...
Read more